Technion
Technion City, Haifa, 3200003, Israel
Overview
“Technikum” - the original German name of the Technion - is a tale of the century. The second industrial revolution created the printing presses and communications infrastructure allowing Jews scattered across the globe to organize in face of rising anti-Semitism. As Jews were often barred from technical education, the establishment of a technical school was a first priority to rebuilding a Jewish homeland. The Technion was to become unique worldwide as a university that would precede, create, shape, and protect a modern state. The cornerstone laid on April 11, 1912, set in motion a century of progress responding to national and global needs. Technion would grow rapidly, becoming a global pioneer in fields such as biotechnology, stem cells, space, computer science, nanotechnology, and energy. Three Technion professors have won Nobel Prizes. As it celebrates its cornerstone centennial in 2012, Technion City is a thriving world center of research and teaching, with 12,850 students and 80 graduate programs trailblazing excellence in research and teaching for the benefit of humanity.
- Total investments
- 10
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 10
Sector focus
- EdTech
- Education
- Higher Education
Investment portfolio
- Q-Factor
Participated · Seed · Apr 2026
Q-Factor was founded in 2026 by four leading physicists from the Weizmann Institute of Science and the Technion and had operated in stealth before its public emergence. The company is developing a full-scale quantum computer using neutral atom technology and says it has identified architectural bottlenecks in existing systems. Its stated goal is to enable continuous scalability of neutral-atom systems toward and beyond one million qubits. Founders include Prof. Nir Davidson, Prof. Ofer Firstenberg, Prof. Yoav Sagi, and Dr. Guy Raz, bringing deep academic and technical leadership to the venture. Q-Factor is backed by a $24 million Seed round and a grant from the Israel Innovation Authority, and counts institutional investors and the founders' academic institutions among its shareholders.
- Mana.bio
Led · Seed · Oct 2023
Mana.bio has developed an integrated experimental and machine-learning platform to design smarter, faster, and more precise lipid nanoparticle delivery formulations for nucleic acid- and genetic-medicine applications. The company focuses on creating protective LNP 'packages' that stabilize volatile RNA molecules for delivery into human cells. Its approach targets RNA-based therapies with potential applications across infectious diseases, cancers and single-gene disorders. Mana.bio emerged from stealth after several years of research and announced its commercial launch alongside scientific papers it planned to present. The startup announced a $19.5 million seed financing and said it will continue advancing drug-discovery and development despite the wartime situation in Israel. CEO and co-founder Yogev Debbi led the announcement and emphasized the company's commitment to partners and patients.
- Nevia Bio
Participated · Seed · Aug 2023
Nevia Bio (formerly Gina Life) applies machine learning to proprietary protein-panel measurements from vaginal swabs to identify biomarker signatures for early and late-stage women’s diseases, notably ovarian cancer. The platform decodes information from vaginal secretions and links a novel biobank to a digital database to enable ML-driven feature identification. Since commencing activity in 2020, the company has run clinical trials and assembled a biobank of more than 900 vaginal-secretion samples from diverse populations and disease states. Nevia plans to use its recent funding to support clinical trials in ovarian cancer, expand its pipeline to additional indications in women’s health, and enhance its data science capabilities. The team is led by Dr. Inbal Zafir-Lavie and Dr. Shlomit Yehudai-Reshef. The company is based in Haifa, Israel.
- VineSight
Participated · Seed · Sep 2022
VineSight is a Tel Aviv, Israel–based platform that tracks, analyses and mitigates online misinformation and toxicity against brands, campaigns and causes. Its AI-driven technology provides accurate, wide-reaching protection across social media platforms and online forums, enabling fast mitigation of reputational threats. The platform is used by some of the world’s largest vaccine manufacturers, Fortune 500 companies, and major non-profits in the U.S. to protect their reputation. VineSight raised $4m in seed funding to support growth. The company intends to use the funds to expand operations, with hiring in R&D and marketing and to broaden its business reach and development efforts.
- Diagnostic Robotics
Participated · Series B · Aug 2022
Diagnostic Robotics builds machine-learning powered preventative care that predicts and helps avert dangerous medical events by offering timely interventions. Its models were trained on 65 million anonymized medical records and the company claims it can reduce ER visits by about 75%. The platform currently tracks roughly 20 high-risk conditions and the company is already serving millions of patients in Israel, South Africa and the U.S., including work with Blue Cross & Blue Shield of Rhode Island. A pilot study of a few hundred patients found the AI-prepared health plan was statistically indistinguishable from a clinician’s. CEO and co-founder Kira Radinsky says the company is expanding from targeting specific high-risk cases toward more holistic provider-driven health goals. Diagnostic Robotics is actively working to identify and mitigate bias in its algorithms and to route patients to cost-saving, often free or low-cost, interventions.